Insights & news

European Union Task Force Publishes Guidance Tackling Medicine Shortage Issues

  • 08/07/2019
  • Articles

A European Union task force set up to address medicine supply problems published on 4 July 2019 two documents on the subject as follows:

  •  Guidance on detection and notification of shortages of medicinal products for Marketing Authorisation Holders in the Union (EEA) (“Document 1” - attached); and
  •  Good practice guidance for communication to the public on medicines’ availability issues (“Document 2” - attached).

The task force was established by the European Medicines Agency (“EMA”) and the Heads of Medicines Agencies (“HMA”), with representatives from the European Commission and national competent authorities, the chairs of the Co-ordination Group for Mutual Recognition and Decentralised Procedures – Human (CMDh) and Veterinary (CMDv), the Good Manufacturing Practices/Good Distribution Practices Inspectors Working Group, the Working Group of Communication Professionals (“WGCP”) and the European Surveillance Strategy Working Group (“ESS WG”).

Document 1 offers guidance to the pharmaceutical industry to facilitate the detection and early notification of medicine shortages to competent authorities. The guidance is based on a common EU definition of the term ‘shortage’ which is said to occur when supply does not meet demand at a national level. In that definition, the notion of supply refers to the total volume of stock of the individual medicinal product that is placed on the market by the Marketing Authorisation Holder. Demand relates to the request for a medicinal product by a healthcare professional, veterinarian or patient in response to a clinical need.

On the basis of this definition, Document 1 explains the issues that form the subject of notification; the party responsible for the notification; the time of notification; the bodies that should be notified; and the information which a notification should cover. Document 1 also contains a handy proposed template for shortage notification. The guidance and template will be implemented in a pilot phase which is currently scheduled to start in the last quarter of 2019.

Document 2 is addressed to EU national competent authorities and EMA and lays out principles and examples of good practices for communication on shortages to the public, including patients and healthcare professionals. The guidance is based on a survey carried out by the task force in all EU Member States to collect information on how issues related to shortages and availability of medicines are measured and communicated to the public.

Significantly, in presenting the guidance, EMA described medicine shortages as a “a key public health priority for the EU network”. At the same time, EMA also acknowledged that medicine “[s]hortages and availability problems are complex with no quick solutions”.


Key contacts

Related practice areas

Related insights

Sign up for updates
    • 11/09/2019
    • Articles

    Stella Kyriakides Commissioner-Designate for Health

    Stella Kyriakides, a member of the Cypriot parliament, a trained psychologist and a forceful advocate of patient rights (she is a past President of Europa Donna, the breast cancer patient group), has been entrusted with the health portfolio by Ursula von der Leyen, the President-elect of the incoming European Commission. Like the other designated Commissioners, Ms. Kyriakides’ appointment still has to be approved by the European Parliament, but with her colleagues she is expected to take up her position in November 2019.

    Read more
    • 09/09/2019
    • Articles

    Belgium - Minister of Economic Affairs Uses Price Regulation Powers against Leadiant's CDCA

    Minister of Economic Affairs Wouter Beke took action against pharmaceutical firm Leadiant and, making use of his price regulation powers, reduced the price of chenodeoxycholic acid Leadiant (“CDCA”), a medicine indicated for the treatment of patients afflicted with cerebrotendinous xanthomatosis, a rare metabolic disorder (“CTX”). CDCA was designated as an orphan medicine in December 2014, but its active substance is no longer patented and has been used for many years as an inexpensive treatment for cholesterol gallstones. In a press release (see attached, only the Dutch version is available), the Minister says that he lowered the price of what would seem to be a presentation of 100 tablets of 250mg of CDCA Leadiant to EUR 3,653.25 ex factory, while Leadiant had sought a price of EUR 14,000 ex factory. The presentation at issue covers the treatment of CTX during approximately one month. The Minister has also urged the Belgian Competition Authority (“BCA”) to review as a matter of priority the alleged abuse of a dominant position of which Leadiant might be guilty. The case before the BCA results from a complaint filed by consumer organisation Test-Aankoop/Test-Achats earlier this year (see, Van Bael & Bellis Life Sciences Newsflashes of 9 April 2019 and 11 February 2019). Additionally, the Minister called on the European Commission to review the rules governing orphan medicines. However, that call is superfluous as an assessment of these rules has already been under way for quite some time (see, Van Bael & Bellis Life Sciences Newsflash of 18 October 2018) and the outcome of this exercise is expected to be high on the agenda of the incoming European Commission.

    Read more
    • 05/09/2019
    • News

    Medicines Cooperation - Sweden to Join International Horizon Scanning Initiative

    On 4 September 2019, the Dutch Minister for Medical Care, Bruno Bruins, announced plans for Sweden to join the impending International Horizon Scanning Initiative (“IHSI”) (see, attached press release). IHSI, which is expected to start in October 2019, is a form of international cooperation that seeks to identify innovative medicines before they reach the market. It will inform decision-making on treatment and budgets in the participating countries. IHSI is just one example of a broader trend of expanding international cooperation on medicines in a range of areas and in varying geographical constellations. Last month, Minister Bruins had already announced that Canada would also become a member of IHSI (see, Van Bael & Bellis Life Sciences Newsflash of 18 July 2019). When airing the intentions of Sweden, Minister Bruins expressed the hope that IHSI would be able to begin operations with 10 member countries. Other known aspiring members include Belgium, Ireland, Luxemburg and The Netherlands.

    Read more

Subscribe to our updates

Please select the practice areas you are interested in: *